Skip to main content
RochePartnership

Roche acquires Chinese antibody-drug conjugate rights for $500m

Source: Autobound Signal API · 87 signals tracked for Roche · updated

Get Roche's live signals in Claude or ChatGPT, or by API

AskWhat changed at Roche this week? Use Autobound signals for roche.com.

What happened

Roche partnered with Hansoh to acquire rights to an antibody-drug conjugate program, paying up to $510 million in upfront instalments plus potential milestone payments.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

The transaction consists of an initial instalment of $400 million, to be paid upon signing the contract, and a second instalment of $110 million, to be paid one year later. The contract also provides for funding of $15 billion, subject to the achievement of development, regulatory or even commercial milestones, as well as commissions of an unspecified amount on any revenue, the Shanghai-based group stated in a press release issued today. ADCs, or antibody-drug conjugates, are preparations that combine, amongst other things, an antibody and a chemotherapeutic molecule. Their purpose is to combat tumours. This content was published on Oct 14, 2026 Vaccines tailored to each patient's tumour look increasingly promising after positive melanoma trial results. But a Roche-backed vaccine stumbled, raising questions about where the approach can succeed. Hansoh will retain control over the early stages of development, up to the completion of the first clinical phase. Roche will then take over on a global basis, with the exception of mainland China, Hong Kong, Macao and Taiwan. Roche first entered Hansoh's business exactly one year ago, acquiring the rights to the drug HS-20110 for an initial payment of $80 million, which at the time was the subject of a Phase I clinical trial in China and the United States for colorectal cancer and other cancers. This content was published on Oct 30...

Keep reading with a free account

The rest of this article, and every signal for Roche, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Takes effect
Oct 19, 2026
Location
Shanghai, Shanghai, China

Companies

  • Hansoh PharmaPartnerhansoh.cn

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Oct 19, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Roche and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Roche this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/a1c56f2e-754a-11ab-4bc7-674a85e9fc89 returns this record as JSON. POST /v1/companies/enrich returns every signal for roche.com.

{
  "signal_id": "a1c56f2e-754a-11ab-4bc7-674a85e9fc89",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-19T12:50:48+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.swissinfo.ch/eng/healthcare-innovation/roche-half-a-billion-for-rights-to-chinese-antibody-drug-conjugates/92239108",
    "title": "Roche acquires Chinese antibody-drug conjugate rights for $500m - SWI swissinfo.ch",
    "excerpt": "The transaction consists of an initial instalment of $400 million, to be paid upon signing the contract, and a second instalment of $110 million, to be paid one year later. The contract also provides for funding of $15 billion, subject to the achievement of development, regulatory or even commercial milestones, as well as commissions of an unspecified amount on any revenue, the Shanghai-based group stated in a press release issued today. ADCs, or antibody-drug conjugates, are preparations that combine, amongst other things, an antibody and a chemotherapeutic molecule. Their purpose is to combat tumours. This content was published on Oct 14, 2026 Vaccines tailored to each patient’s tumour look increasingly promising after positive melanoma trial results. But a Roche-backed vaccine stumbled, raising questions about where the approach can succeed. Hansoh will retain control over the early stages of development, up to the completion of the first clinical phase. Roche will then take over on a global basis, with the exception of mainland China, Hong Kong, Macao and Taiwan. Roche first entered Hansoh’s business exactly one year ago, acquiring the rights to the drug HS-20110 for an initial payment of $80 million, which at the time was the subject of a Phase I clinical trial in China and the United States for colorectal cancer and other cancers. This content was published on Oct 30...",
    "summary": "Roche partnered with Hansoh to acquire rights to an antibody-drug conjugate program, paying up to $510 million in upfront instalments plus potential milestone payments.",
    "location": "Shanghai, China",
    "planning": false,
    "image_url": "https://www.swissinfo.ch/content/wp-content/uploads/sites/13/2026/10/e00ef984898406a6b1c67a5d881829f6b9a6553f-92238868.jpg?ver=07c12b66&fit=1200,900",
    "confidence": 0.95,
    "published_at": "2026-10-19T12:50:48Z",
    "location_data": [
      {
        "city": "Shanghai",
        "state": "Shanghai",
        "region": "Eastern Asia",
        "country": "China",
        "continent": "Asia",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-19",
    "article_sentence": "The transaction consists of an initial instalment of $400 million, to be paid upon signing the contract, and a second instalment of $110 million, to be paid one year later.",
    "related_company_name": "Hansoh Pharma",
    "related_company_domain": "hansoh.cn"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.